CN Mobile Logo


Prevention and management of radiation toxicity

Prevention and management of radiation toxicity

The aim of radiation oncology is the achievement of uncomplicated locoregional
control of malignancy by the use of radiation therapy (RT). Accomplishing this
goal requires precise knowledge of tumoricidal and tolerance doses of the various
normal tissues at risk within the RT field.

Types of RT injury

Radiation injuries can be divided into functional impairment and oncogenesis.
There are also different phases of RT injury.

Early effects are usually seen during treatment or within the first few weeks
after its completion. These reactions are common, can be significant and symptomatic,
but eventually seem to heal completely. Nevertheless, despite what
may appear to be total recovery, significant residual damage is often present.

Intermediate effects typically occur several weeks to months after the
completion of RT.

Late effects are usually rare and are encountered many months to years after
RT. Functional impairments may take a long time to become apparent; an example
is memory problems in children who have received cranial irradiation.
Oncogenesis is usually a late effect of RT.

Tolerance doses of radiation

Numerous studies have attempted to specify RT tolerance doses for the various
tissues and structures of the body. The minimal tolerance dose (TD 5/5) and
maximal tolerance dose (TD 50/5) refer to a severe complication rate of 5% and
50%, respectively, within 5 years of RT completion (Table 1). These tolerance
doses have been valuable but were drastically revised recently because of the
advent of combined-modality therapy (see section on "Combined chemotherapy
and irradiation") and altered RT fractionation regimens.

Chemoradiosensitivity of normal tissues Cell-cycle kinetics, mitotic behavior,
and differentiation determine the chemoradiosensitivity of normal tissues.

The dividing cell is more vulnerable to RT than the quiescent cell, especially
one that is functionally mature.

Dose-limiting organs and tissues have been divided into three classes according
to their RT tolerance doses and importance to survival:

  • Class I organs are those in which irreparable damage leads to death or
    severe morbidity.
  • Class II organs are those in which damage is associated with moderate
  • Class III organs are those in which damage produces minimal

Combined chemotherapy and irradiation

In combined-modality therapy, several temporal strategies with different rationales
are utilized: concurrent RT and chemotherapy, local RT followed by
chemotherapy, chemotherapy followed by local RT, and alternating chemotherapy
and RT cycles.

When used in combination, RT and chemotherapy can act independently, with
each mode acting in isolation in different parts of the body. The combined use
of the two modalities can also result in increased or decreased therapeutic activity,
as well as various possible adverse interactions:

  • Damaging effects of RT on the target organ can be increased by chemotherapy.
    Some chemotherapeutic agents are RT enhancers or
    reactivators, which, when used concurrently with RT, can produce reactions
    in various tissues at much lower RT doses than expected.
  • Damaging effects of chemotherapy on the target organ can be increased
    by RT.
  • Independent injuries can be caused by the individual treatment modality
    in the same organ, which can combine to increase the resulting
    dysfunction. Subclinical residual injury from one treatment modality
    may be uncovered by the subsequent use of a seemingly safe dose of
    another modality.
  • An injury can be produced that is not commonly seen with either modality

The inherent difficulty in understanding these consequences is further complicated
by the number of chemotherapeutic agents generally combined in
treatment protocols and the variety of conventional or altered RT delivery

Quantification of treatment toxicity

In addition to therapeutic efficacy, quantification of RT toxicity is crucial for
evaluating new regimens and selecting therapy for individual patients. The
optimal therapeutic ratio requires not only complete tumor clearance but also
minimal residual injury to surrounding vital normal tissues.

Morbidity scoring schemes developed by the Radiation Therapy Oncology
Group (RTOG), European Organization for Research and Treatment
of Cancer (EORTC), and the National Cancer Institute (NCI) are used
most commonly. The late effects of normal tissues (LENT) scoring system
was adopted by the RTOG and EORTC in 1995. It graded toxicity according
to four parameters, denoted by the acronym "SOMA," which
stands for subjective (symptoms reported), objective (signs on examination),
management (instituted), and analytic (tissue function assessed by
objective diagnostic tools).

In 1997, the NCI with other American (eg, RTOG) and international cooperative
groups, the pharmaceutical industry, and the World Health Organization
(WHO) revised and expanded the Common Toxicity Criteria (CTC) by integrating
systemic agent, radiation, and surgical criteria into a comprehensive
and standardized system. The CTC v. 2.0 replaced the previous NCI, CTC,
and the RTOG Acute Radiation Morbidity Scoring Criteria.

The third version of the CTC has been renamed Common Terminology Criteria
for Adverse Events v. 3.0 (CTCAE v. 3.0). The purpose of renaming it was
to move away from the term toxicity, which implies causation and does not fit
the jargon commonly used across all modalities. It is anticipated that after October
2003, all NCI-sponsored trials will use CTCAE v. 3.0, which represents
the first comprehensive multimodality grading system to include both acute
and late effects. The new system is designed for application to all modalities.


The incidence and severity of normal tissue toxicity from RT depend on a wide
variety of factors, including total dose, fraction size, interval between fractions,
quality and type of RT, dose rate, intrinsic radiosensitivity, and specific tissue
irradiated. The most common toxic effects seen in different organ systems are
outlined here and in Table 2, along with recommended treatments. Where appropriate,
the specific effects of chemoradiation therapy are discussed separately.


Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.